A Disease That Had Nothing

For decades, a Sanfilippo diagnosis came with no treatment. Children with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) develop, then plateau, then lose what they had learned: words, skills, independence. Care meant managing symptoms and supporting families through a decline everyone could see coming.

On 17 September 2026, that changed in the United States. The FDA approved rebisufligene etisparvovec, also known as UX111 during development. It is the first FDA-approved treatment for MPS IIIA and the first gene therapy for the disease.

I've spent more than 22 years in rare disease commercialisation. My first reaction was relief for the families who fought for this. My second was a question that every European launch team should be asking this week: what happens to the children here while Europe catches up?

What the FDA Approved

These are facts from the FDA announcement, the US prescribing information and the sponsor's release, not my interpretation.

  • Indication. Treatment of the neurologic manifestations of MPS IIIA in paediatric patients with preserved neurodevelopmental function. Those last words matter, and I come back to them below.
  • Mechanism. A one-time intravenous infusion of an AAV9 vector that delivers a working copy of the SGSH gene, so cells can make sulfamidase and break down heparan sulfate.
  • Evidence. An open-label, single-arm, multicentre study plus long-term follow-up. The FDA describes treated children aged about 2 to 5 years who maintained or improved cognitive function, compared with an untreated historical control cohort whose expected course is plateau and decline.
  • The headline number. According to the label and the company, 17 treated children in the modified intention-to-treat (mITT) population were compared with 27 untreated children from a natural history cohort. The difference in mean change in Bayley-III Cognitive raw score between 24 and 60 months of age was 23.5 points in favour of treatment (p<0.0001). Treated children gained on average; untreated children lost.
  • Biomarker and durability. The sponsor reports reduced heparan sulfate in cerebrospinal fluid across age groups and clinical follow-up of up to nearly eight years.
  • Who was treated. In the mITT population, children were treated at a mean age of 21.8 months. Those older than two needed a cognitive developmental quotient of at least 60. All had anti-AAV9 antibody titres below 1:100.
  • What the infusion demands. Corticosteroids start the day before infusion and continue for at least eight weeks. The label lists warnings for hepatotoxicity, thrombocytopenia and thrombotic microangiopathy, plus liver and platelet monitoring for months afterwards. It does not recommend treatment above an anti-AAV9 titre of 1:100, and notes that no FDA-authorised test for those antibodies exists yet.
  • Access model. Treatment runs through US Qualified Treatment Centers, supported by the sponsor's patient-support programme. Reuters and Fierce Pharma report a US list price (WAC) of $3.95 million, announced by the company on its approval call.

The sponsor estimates 3,000 to 5,000 patients with MPS IIIA in commercially accessible geographies and a median life expectancy of 15 years. Those are the company's figures, not a registry count.

What the data don't say

Some limits belong here. The evidence comes from a small, single-arm study compared with an external control, which is common in ultra-rare disease but always open to debate about comparability. The label covers children whose neurodevelopment is still preserved. It says nothing about children who have already lost significant function, and it isn't an EU or UK label. Rebisufligene etisparvovec is not authorised by the EMA or the MHRA. In Europe it is still an investigational therapy.

Why This Matters Commercially

From here on, this is my commercial interpretation for rare disease teams in Europe and the Benelux, not a claim from the FDA or the sponsor.

1. The window is the product

In most launches, eligibility is a box on a form. Here it's the whole story. A therapy that preserves function can only preserve what a child still has. Every month between first symptoms and infusion is a month of potential loss.

That turns diagnosis speed into a commercial and ethical priority. Sanfilippo is often recognised late, after speech delay or behavioural problems have been put down to something else. The diagnostic tools I wrote about in March's article on AI-driven medicine in rare disease care aren't a side project for a disease like this. Disease awareness among paediatricians, child neurologists and developmental clinics is what decides who is still eligible when access arrives.

2. Europe is now waiting, and waiting has a cost

US approval creates a two-speed reality. A family in Ohio has a qualified centre. A family in Ghent or Utrecht has a diagnosis, a US press release and a calendar. That gap won't be quiet. Expect pressure through patient organisations, cross-border care requests, privately funded travel to the US and questions to every metabolic centre about compassionate use.

None of those routes is simple for an AAV gene therapy. It needs a qualified site, antibody screening, a steroid regimen and months of follow-up, which a family can't easily organise from the other side of the Atlantic. Teams that treat this period as "pre-launch, nothing to do" will lose the trust of the centres and families they need later.

3. Site qualification is the real launch ceiling

In the US, the model is a network of qualified centres. In Europe, it will almost certainly be a small number of metabolic and gene therapy centres per country. In the Benelux, that could mean only a handful.

What qualification needs here is specific: frozen storage at or below −60 °C, handling of a viral vector, anti-AAV9 serology with a test that isn't yet standardised, peri-infusion corticosteroids, and monitoring of liver function, platelets and TMA risk. Each item is a conversation with hospital pharmacy, biosafety, hepatology and haematology. Those conversations take months, and none of them need a marketing authorisation to begin.

4. AAV9 serology is a hidden filter

Pre-existing antibodies to AAV9 rule some children out. That shrinks the treatable population in a way most forecasts underweight, and it puts a laboratory question at the front of the patient journey. Who runs the assay in Europe? How fast does a result come back? Who tells a family their child isn't eligible? These are operational questions with emotional weight, and they belong in launch planning, not after it.

5. One-shot economics meet European payers

A list price close to $4 million for a single infusion turns the payer conversation into a lifetime-value discussion paid up front. The company argued on its approval call that the lifetime cost of care for a child with Sanfilippo can exceed $8 million. European HTA bodies will weigh that kind of claim against a small single-arm dataset, an external control and limited long-term certainty.

In my view, outcomes-based or instalment-style agreements will come up quickly. The real question is which outcome you can measure: cognitive scores, biomarkers, or the milestones families actually care about. As an advanced therapy, any EU filing also falls under the EU Joint Clinical Assessment process, which has covered ATMPs since January 2025. Evidence planning now has to serve a European clinical assessment and several national price negotiations at once.

What EU Launch Teams Should Do Now

This is practitioner judgment from orphan launches, not guidance from any company or regulator. It applies to rebisufligene etisparvovec and to anyone with a CNS gene therapy one or two years behind it.

1. Start before the CHMP opinion, not after it. The work that sets launch speed, such as centre mapping, site qualification, payer pre-engagement and a patient-finding strategy, doesn't depend on an EU decision. Begin it while the regulatory review runs. (This is the logic behind our approach to orphan drug launches in Europe.)

2. Map every child, with the patient community. In ultra-rare disease you count patients by name. Work with metabolic centres and patient organisations, within GDPR, to understand how many diagnosed children are likely to have preserved function, and how many are diagnosed each year. That number is your forecast.

3. Build the bridge before families build their own. Decide early how you will respond to compassionate use, named-patient and cross-border requests, consistent with local rules and supply. A clear, honest position protects patients and protects the relationship. Silence pushes families towards routes nobody can support well.

4. Qualify centres and labs in parallel. Pharmacy, biosafety, steroid protocols, liver and platelet monitoring, and AAV9 antibody testing all need a lead time. Treat them as one workstream with one owner.

5. Prepare the payer story for one-shot reality. Model budget impact for a small, front-loaded patient pool, then a lower steady flow of newly diagnosed children. Prepare outcomes-based options before a payer asks for them.

6. Put experienced leadership in place early. Many companies bring a gene therapy into Europe without a country team. Hiring a full affiliate for a handful of patients a year rarely makes sense at the start. An interim or fractional commercial lead can build the centre network, the access plan and the payer case, then hand over or scale. (That's the model behind our interim commercial director work in the Benelux.)

What to Watch

  1. The European filing. When an EU marketing authorisation application is validated and reviewed, and how the CAT, CHMP and Joint Clinical Assessment timelines line up.
  2. UK evaluation. The UK MPS Society says UK evaluation started in mid-September, with NICE submissions expected around mid-November 2026 and a first NICE meeting around mid-April 2027.
  3. Real-world US launch data. How many children prove eligible after AAV9 screening, and how quickly qualified centres treat them.
  4. Payment models. Whether one-shot pricing for an ultra-rare CNS gene therapy lands as outcomes-based, instalment or conventional agreements, in the US and then in Europe.

Hope With a Deadline

Sanfilippo families have heard the word "hope" for a long time. This month it finally came with an approved therapy. In Europe, it also comes with a deadline, because the children who could benefit most are the ones whose abilities are still intact today.

The science has done its part. Turning a US approval into treated European children is now commercial, operational and access work. That's work rare disease teams know how to do, and it should start now.

Update, October 2026: On 2 October 2026, the sponsor announced that the EMA had validated its marketing authorisation application for rebisufligene etisparvovec. Validation starts the formal scientific review; it is not an approval. The company also confirmed that the application falls within the EU Joint Clinical Assessment framework. On 7 October, the UK MPS Society noted that there are currently no UK or EU sites approved to deliver rebisufligene etisparvovec. I've since written more broadly about how one-time therapies change commercial models in One-Shot Therapy Is Here.